Hims & Hers introduced a new tracker to monitor shortages of GLP-1 weight loss and diabetes drugs, responding to the FDA's decision to end the compounded versions, Yahoo Finance reported Nov. 13.

Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.

Courts have long deferred to CMS’s decisions on implementation of laws that govern Medicare. The overturning of the Chevron ...

A recent study that found there has been a massive increase in type 2 diabetes cases worldwide since 1990 is an indication ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

Why is bulldozer justice relevant to the UPSC Exam? What significance do topics like the weight-loss drug Semaglutide, the ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

The sizeable new round follows the announcement of phase 1 data for its lead asset MET-097i in September and, according to ...

A manufacturer-funded study found a significant decrease in annual total medical costs in patients with overweight/obesity ...

Novo Nordisk, which manufactures weight-loss drug Wegovy and diabetes medication Ozempic, has asked the US authorities to ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...